We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

I have been bullish towards the Vanguard Total Stock Market ETF lately. Read why I now downgrade the fund from buy to hold.

We recently compiled a list of the 8 Best Vanguard Funds to Invest In for Retirees. In this article, we are going to take a look at where Vanguard Mega Cap Growth Index Fund (NYSE:MGK) stands ...

What’s the full story? Seaport lays out a bullish case, starting with the massive total addressable market for groceries, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...